Medical Therapy. Efficacy or Lack of Efficacy

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients – An Open-Label Phase 2 Study

Toru Iwasa, Ryo Inuzuka, Hiroshi Ono, Yuichiro Sugitani, Hirokuni Yamazawa, Chihiro Hiraishi, Naoki Shiota, Shinichi Tanaka, Chieko Yamamoto, Ken-ichi Kurosaki, Masaru Miura, Satoshi YasukochiNational Cerebral and Cardiovascular Center. University of Tokyo. National Center for Child Health and Development. Japan Community Health Care Organization Kyushu Hospital. Hokkaido University. Nippon Shinyaku Company. Tokyo Metropolitan Children’s Medical Center.

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients – An Open-Label Phase 2 Study Read More »

Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age

Shin Kato, Yohei Minamitani, Miku Hosokawa, Toshinori Nakashima, Sota Iwatani, Katsuya Hirata, Arata Oda, Takushi Hanita, Masafumi Miyata, Fumihiko Namba, Masayuki Ochiai, Atsushi Nakao, Seiji Yoshimoto, Daichi Suzuki, Erika Ota, Hidehiko Nakanishi, on behalf of the Japan Society for Neonatal Health and DevelopmentJapanese Red Cross Aichi Medical Center Nagoya Daini Hospital. Saitama Medical Center and

Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born <34 weeks) after 7 days of age Read More »

Sotatercept: A New Era in Pulmonary Arterial Hypertension

Suneesh C. Anand, Muhammad Furqan, Adriano R. Tonelli, Daniela Brady, Avi Levine, Erika B. Rosenzweig, William H. Frishman, Wilbert S. Aronow, Gregg M. LanierHillcrest Hospital and Cleveland Clinic. New York Medical College, Maria Fareri Children’s Hospital of Westchester and  Westchester Medical Center.United States Cardiology in ReviewCardiol Rev 2025; DOI: 10.1097/CRD.0000000000000837 AbstractPulmonary arterial hypertension (PAH) is a

Sotatercept: A New Era in Pulmonary Arterial Hypertension Read More »

Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension

Cara Morgan, Nikmah Idris, Kathy Elterefi, Luca Di Ienno, Andrew Constantine, Sadia Quyam Roberta Bini, Shahin MoledinaGreat Ormond Street Hospital for Children. Queen Elizabeth Hospital. Institute of Cardiovascular Sciences University College London. United Kingdom Pulmonary CirculationPulm Circ 2024;DOI: 10.1002/pul2.70011 AbstractThe aim of this single-centre retrospective observational study was to evaluate the safety, tolerability, and efficacy of

Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension Read More »

The Role of Nitric oxide in the sweep gas for patients receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass

Roberto Chiletti, Sophie H. Fincher, Stephen B. Horton, Giles J. Peek, Paul Checchia, Warwick ButtRoyal Children’s Hospital and University of Melbourne. University of Florida. Texas Children’s Hospital and the Baylor College of Medicine. Australia and United States Canadian Journal of CardiologyCan J Cardiol 2024; DOI: 10.1016/j.cjca.2024.12.027 AbstractNitric oxide (NO) was proclaimed the 1992 “molecule of the

The Role of Nitric oxide in the sweep gas for patients receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass Read More »

Influence of inhaled nitric oxide on bronchopulmonary dysplasia in preterm infants with PPHN or HRF at birth: a propensity score matched study

Xue-rong Huang, Lian Wang, Guo-bao Liang, Sheng-qian Huang, Bao-ying Feng, Lu Zhu, Xu-fang Fan, Mu-lin Yao, Jing Zhang, Meng-jiao Wang, Zhi Zheng, Yao Zhu, Wen-li Duan, Zhan-kui Li, Jian Mao, Li Ma, Fa-lin Xu, Fan Wu, Qiu-fen Wei, Ling Liu, Xin-zhu LinWomen and Children’s Hospital of Xiamen University School of Medicine. Xiamen Key Laboratory of

Influence of inhaled nitric oxide on bronchopulmonary dysplasia in preterm infants with PPHN or HRF at birth: a propensity score matched study Read More »

Fetal-to-Neonatal Transition of an Infant with Transposition of the Great Arteries and Intact Ventricular Septum: A Case Report

Jesse A. Weeda, Arjan B. te Pas, Monique C. Haak, Nico A.Blom, Roel L.F. van der PalenWillem-Alexander Children’s Hospital and Leiden University Medical Centre. Netherlands Biomedicine HubBiomed Hub 2024;DOI: 10.1159/000542723 AbstractIntroduction: Transposition of the great arteries (TGA), especially with intact ventricular septum (TGA-IVS), presents unique challenges during fetal-to-neonatal transition, which can contribute to developing persistent pulmonary hypertension

Fetal-to-Neonatal Transition of an Infant with Transposition of the Great Arteries and Intact Ventricular Septum: A Case Report Read More »

Honokiol and Nicotinamide Adenine Dinucleotide Improve Exercise Endurance in Pulmonary Hypertensive Rats Through Increasing SIRT3 Function in Skeletal Muscle

Min Li, Brittany Alexandre McKeon, Sue Gu, Ram Raj Prasad, Hui Zhang, Sushil Kumar, Suzette Riddle, David C. Irwin, Kurt R. StenmarkUniversity of Colorado Anschutz Medical Campus.United States International Journal of Molecular SciencesInt J Mol Sci 2024; 25: DOI: 10.3390/ijms252111600 AbstractPulmonary hypertension (PH) significantly impairs exercise capacity and the quality of life in patients, which is

Honokiol and Nicotinamide Adenine Dinucleotide Improve Exercise Endurance in Pulmonary Hypertensive Rats Through Increasing SIRT3 Function in Skeletal Muscle Read More »

Inhaled Nitric Oxide Treatment of Early Pulmonary Hypertension to Reduce the Risk of Death or Bronchopulmonary Dysplasia in Infants Born Extremely Preterm: A Masked Randomized Controlled Trial

Hussnain Mirza, Jorge Garcia, Matthew Zussman, Rajan Wadhawan, Julie Pepe, William OhAdvent Health for Children.United States Journal of PediatricsJ Pediatr 2024; DOI: 10.1016/j.jpeds.2024.114427 AbstractObjective: To determine whether inhaled nitric oxide (iNO) treatment of early pulmonary hypertension (PH) would decrease the risk of death or bronchopulmonary dysplasia (BPD) among infants born extremely preterm.Study design: This was a single-center, masked,

Inhaled Nitric Oxide Treatment of Early Pulmonary Hypertension to Reduce the Risk of Death or Bronchopulmonary Dysplasia in Infants Born Extremely Preterm: A Masked Randomized Controlled Trial Read More »

Treprostinil Use in the NICU

Diana LeeUniversity of Pennsylvania School of Nursing.United States Advances in Neonatal CareAdv Neonat Care 2024; 24: 554-560DOI: 10.1097/ANC.0000000000001218 AbstractBackground: Treprostinil is a prostacyclin analogue that is frequently used in the pediatric and adult population to treat pulmonary hypertension; however, it is not often a drug of choice for patients in the neonatal intensive care unit (NICU).Purpose: To evaluate

Treprostinil Use in the NICU Read More »

Scroll to Top